shr-2554
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 12, 2024 (NCT06519526)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
EZH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07311408 | Phase 2 | Jan 1, 2026 | China Medical University |
| NCT06519526 | Phase 2 | Aug 12, 2024 | Fudan University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1